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0951-7375  2014 Wolters Kluwer´ a bMiren Iturriza-Gomara and Benjamin LopmanPurpose of review
To provide an overview of the burden of norovirus disease in healthcare settings and the factors
responsible for outbreaks in these institutions; to assess progress on interventions aimed at reducing the
burden of norovirus disease.
Recent findings
Norovirus outbreaks in healthcare settings are driven by confluence of viral diversity, the built environment,
and host factors. Some of these characteristics may be modifiable and the target of successful interventions.
Summary
Most norovirus outbreaks in hospital and residential care institutions are associated with a particular
genotype, known as GII.4. The persistence of norovirus is associated with strain diversity, which is driven
by immune evasion and viral adaptation to interaction with a variety of human histo-blood group antigens.
The healthcare environment presents serious challenges for control, both because of the physical structure
of the built space and the high levels of contact among patient populations who may have compromised
hygiene. Increased vulnerability among the populations in healthcare institutions is likely to be
multifactorial and may include the following: nutritional status, immunodeficiency or senescence, chronic
inflammation, and microbiome alterations. Current control measures are based on general infection
control principles, and treatment is mainly supportive and nonspecific. Vaccines and antiviral agents are
being developed with promising results, but none are currently available.
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cited.Noroviruses are endemic in the human population,
affect people of all ages, and are recognized as the
leading cause of infectious intestinal disease across
the age range [1–3]. Norovirus outbreaks are com-
mon in many settings but predominate where there
are high levels of contact and potentially comprom-
ised hygiene, such as populations in hospitals and
nursing homes. In addition to the health impacts,
healthcare-associated outbreaks pose a significant
operational and economic burden to health systems
[4,5
&
,6]. In otherwise healthy populations norovirus
gastroenteritis is generally mild and self–limiting,
but there is increasing evidence that it may lead to
long-term sequelae [7,8] and contribute to excess
mortality in the elderly and the immunocompro-
mised [9–16] who are inordinately affected in
healthcare-associated outbreaks. At present, there
are no specific interventions rigorously proven to
prevent transmission and/or disease [17–19,20
&
].
The factors that facilitate sustained transmission
in health and long-term care settings are likely to be
the result of a combination of the built environ-
ment, behavior patterns associated with patients,
visitors and staff, the characteristics of the norovirusilliams & Wilkins. Unau
Health | Lippincott Williams & Wilksusceptibility to disease [21,22] (Fig. 1). Noroviruses
are a highly diverse set of RNA viruses, but gen-
ogroup 2 genotype 4 (GII.4) strains overwhelmingly
cause these healthcare outbreaks, with elderly
patients and the immunocompromised being the
most frequently and/or severely affected. Health
and residential-care institution-associated out-
breaks occur all year round; however, they peak in
the winter months, coinciding with other winterthorized reproduction of this article is prohibited.
ins www.co-infectiousdiseases.com
CKEY POINTS
 Noroviruses are the most common cause of outbreaks
of infectious intestinal disease, and the majority of these
outbreaks occur in healthcare facilities, including
nursing homes and hospitals.
 Noroviruses are a diverse group of RNA viruses; one
particular genotype (known as GII.4) overwhelmingly
predominates in healthcare outbreaks.
 Vulnerable patient populations are affected in
healthcare-associated outbreaks of norovirus. Although
norovirus is typically a mild infection in the general
population, in these groups severe infections,
sometimes even resulting in death, can occur.
 The reasons for increased vulnerability of these patient
populations may include the following: nutritional
status, immune-deficiencies and senescence, chronic
inflammation, and microbiome alterations.
 Lacking an evidence base for the efficacy of specific
interventions, control measures are based on general,
but sound, infection control principles. Vaccines and
antiviral agents against norovirus have shown promise
as preventive and therapeutic agents, respectively, but
neither is currently available.
Gastrointestinal infectionspressures on the healthcare system [23,24]. Norovi-
ruses are likely to be introduced into these settingsopyright © Lippincott Williams & Wilkins. Unautho
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438 www.co-infectiousdiseases.comfrom the community through infected patients,
visitors and/or staff, who may either be asympto-
matic, presymptomatic (i.e., incubating) or sympto-
matic at the time of admission. Following
introduction, the hospital environment can facili-
tate transmission. Although healthcare outbreaks
are clearly linked to disease in the community,
they are also distinct in terms of the intensity of
their seasonality, overwhelming predominance of a
single genotype and impacts on a vulnerable popu-
lation. Here, we review the recent data on the viral,
environmental, and host factors that are associated
with the high disease burden and the challenges in
controlling norovirus in healthcare settings.THE VIRUS AND ROUTES OF
TRANSMISSION
Noroviruses are a highly diverse group of single-
stranded RNA viruses. There are two genogroups
(I and II), comprising 9 and 22 genotypes, respec-
tively [25], that principally cause disease in humans.
Despite this great diversity, norovirus outbreaks in
healthcare settings are caused overwhelmingly by
GII.4 strains. These viruses also are associated with
more severe outcomes, even after accounting for the
more vulnerable case-mix that they tend to infect in
healthcare settings [26]. The emergence of particular
GII.4 variants correlates with periodic increases inrized reproduction of this article is prohibited.
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Norovirus in healthcare settings Iturriza-Go´mara and Lopmanthe number of outbreaks and the overall magnitude
of the annual norovirus epidemic wave. This
phenomenon, similar to the antigenic shift seen
with influenza viruses, is thought to be due to the
emergence of antigenic variants for which there is
little or no population immunity [27–31].
Norovirus infections in hospitals and nursing
homes are associated with high attack rates (median
50%, range 9–78%) and may be protracted, with a
mean duration of 16 days (range 3–44) and 19 days
(range6–92) innursinghomesandhospitals, respect-
ively, according to one systematic review [17]. Nor-
oviruses are easily transmitted by the fecal–oral route
through direct contact with infected individuals and
contaminated surfaces, and by aerosol dispersal fol-
lowing vomiting episodes that subsequently lead to
contamination of the surrounding environment
[32,33]. Widespread environmental contamination
occurs duringoutbreaks inhealthcare settings, but its
precise origin and contribution to spread remain
poorly understood [34,35]. Detection of norovirus
genetic material on environmental surfaces has been
correlated with ongoing and recurring outbreaks in
several settings, including healthcare institutions
[36,37]. High viral loads in faeces and vomitus during
and after the acute phase of infection, the low infec-
tious dose and the short incubation time associated
with noroviruses are the key factors associated with
transmission in semiclosed environments [38,39
&
].
Spatial proximity to a symptomatic case has been
identified as an important factor for the propagation
ofnorovirus infections [22,40,41].Althoughthereare
both symptomatic and asymptomatic infections
among patients and staff, it appears that sympto-
matic patients are the main drivers of transmission
[40].THE HEALTHCARE ENVIRONMENT,
PREVENTION AND OUTBREAK CONTROL
Although the role of ward closures, specific cleaning
regimes and case isolation in controlling norovirus
in healthcare institutions continues to be debated,
the evidence to date suggests that the best strategy
for preventing the spread of norovirus infections in
hospitals is likely to be by preventing direct contact
between infected and susceptible patients. The
introduction of norovirus into the hospital environ-
ment from the community may be practically inevi-
table; curtailing spread in the hospital could be
significantly curtailed through the isolation of
patients in single occupancy rooms while receiving
care. As proximity to a symptomatic case is a driver
of norovirus outbreaks, transmission of norovirus
infections is likely to be promoted in an environ-
ment in which care is provided in wards with highCopyright © Lippincott Williams & Wilkins. Unau
0951-7375  2014 Wolters Kluwer Health | Lippincott Williams & Wilkpatient density with limited physical barriers and
shared toilet facilities, coupled with patient move-
ment between assessment units and final inpatient
destination wards. In nursing homes, density of
room occupancy is likely less of a driver of trans-
mission; residents are more mobile and self-suffi-
cient and gather in communal use rooms, all of
which can facilitate norovirus transmission.
Hospital systems (i.e., acute care facilities) across
the developed world, including those in Europe,
Japan, Australia, and Canada, are commonly
affected by norovirus outbreaks. The United States
is an exception to this. Although long-term care
facilities are the predominant setting for outbreaks
in the United States (>60% of all norovirus out-
breaks), less than 5% of reported outbreaks are in
acute care hospital settings [42]. The large difference
in rates of reported hospital outbreaks between the
Unites States and other affluent countries may be
suggestive of a lower incidence in the United States,
but a survey of infection preventionists found nor-
oviruses to be the number one cause of infectious
disease outbreaks in United States hospitals [43], so
the degree of under-reporting from hospital out-
breaks remains a question.
The main approaches to preventing and con-
trolling norovirus outbreaks, common across several
national guidelines, include promotion of hand
hygiene, patient isolation (separation of sympto-
matic patients) and cohorting (grouping of patients
based on symptoms), staff exclusion from work,
visitor restrictions, enhanced environmental clean-
ing and disinfection, and closures of units. The
specifics of these control measures are beyond the
scope of this review; published guidelines should be
consulted for further details [18,19,44–46]. Areas of
controversy include the effectiveness of alcohol-
based hand sanitizers and closures of affected units
to new admissions. Despite widespread use, the
evidence on the effectiveness of alcohol-based hand
sanitizers is inconclusive [47,48], so they should be
used in addition to, not instead of, hand washing
during outbreaks. Some studies suggest that ward
closure is effective at reducing cases and the
duration of outbreaks [4]. Because it is a costly
and disruptive intervention, ward closure remains
controversial and guideline documents do not con-
sistently recommend it for all outbreaks [44].HOST FACTORS ASSOCIATED WITH
POPULATIONS IN HEALTHCARE SETTINGS
Both host genetic factors and acquired immunity
play a role in norovirus susceptibility. Genetic resist-
ance to norovirus infection is related to human
histo-blood group antigen (HBGA) genotype.thorized reproduction of this article is prohibited.
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CGastrointestinal infectionsIndividuals who express HBGA on cell surfaces and
in body fluids, termed secretors, are generally
susceptible to a wider range of norovirus strains
whereas nonsecretor individuals tend to be signifi-
cantly more resistant to norovirus infections
[27,49]. However, susceptibility and resistance pat-
terns differ according to norovirus strain [50]. The
ability of norovirus-specific antibodies to bind to
norovirus capsid sites involved in attachment to
HBGA is believed to correlate with protection
[28,31,51
&&
, 52,53,54
&&
].
Predominance of GII.4 strains may be related to
both the ability of this genotype to evade herd
immunity through continuous evolution, but also
because of its ability to attach to a wider range of
cellular host receptors that are present in the
majority of the population [55].
In immunocompromised patients, norovirus can
cause chronicdehydratingdiarrhea, leading to severe
disease complications and sometimes mortality
(reported to be up to 25%) [12,14–16,56
&&
]. The
evolution of GII.4 strains within a long-term
shedding immunocompromised patient has been
observed to lead to the generation of antigenically
distinct strains, supporting the hypotheses that long-
term shedders in healthcare settings may serve as a
source for the emergence of epidemic strains [57
&&
].
Although children have the highest incidence in
the community [58], among hospital in-patients
the elderly suffer a longer duration of illness with
more severe symptoms, contributing to excess
mortality [9,10]. Immunosenescence may be one
contributory factor; this consequence of aging is
increasingly recognized as a major risk factor leading
to increases in inflammation, autoimmunity, cancer,
susceptibility to gastrointestinal infections, and
poor response to vaccines, which is particularly acute
among theelderly in residential care [59,60]. Another
risk factormay be ongoing statin use, whichhas been
implicated as a risk factor for norovirus disease [11].
Consistent with this are in-vitro and in-vivo exper-
iments that have demonstrated that statins can
increase norovirus pathogenicity and reduce the
infectious dose required to cause disease in animal
models [61
&
,62]. Considering the increasing and
widespread use of these types of drugs in an aging
population globally, a better understanding of the
relationship between statins and the risk of norovirus
infection and disease and of age related waning
immunity is needed.
Another area gaining interest is the interaction
between the gut microbiota and noroviruses [63
&
].
Disruptionof the gutmicrobiota followingnorovirus
infection has been described in some patients inde-
pendent of age, resulting in a loss of diversity and
increased Proteobacteria, whichmay potentially leadopyright © Lippincott Williams & Wilkins. Unautho
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infection irritablebowel syndrome [7,64].Microbiota
composition changes significantly with age [65]; a
decrease of bifidobacteria, which are thought to play
an immune-modulatory role and represent import-
ant components of a ‘healthy’ gut microbiota, is
known to be associated with the aging process.
Among the elderly, the microbiota associated with
those in long-term care is less diverse than among
those that remain in the community, and that the
loss of the ‘community’-like microbiota is associated
with ill-health [66]. Kuss et al. [67] demonstrated that
the gut flora directly impacts on infectivity and
pathogenicity of viruses by facilitating entry and
infection through direct virus-bacteria interactions,
and the recentobservation thatnorovirus canbind to
HBGA-like molecules present in certain gut bacteria
provide an interesting avenue to explore the relation-
ship betweenmicrobiota composition and norovirus
infection, with a potential to inform new therapeu-
tic approaches [63
&
]. Therefore, nutritional status,
immunosenescence, inflammation, the microbiome
and even whether an individual lives in the com-
munity or in an institution may all be associated
with aging and susceptibility to norovirus. As such,
a holistic approach may be required to better under-
stand host factors associated with norovirus disease,
and ultimately to inform the design of therapy and
prevention.
Other healthcare associated infections, such as
Clostridium difficile diarrhea, are associated with
altered microbiota composition characterized by a
loss of diversity [68]; repopulation of the gut
environment with ‘healthy’ microbiota can reverse
chronicC. difficile diarrhea [69]. Recently, the acqui-
sition of norovirus infection though fecal transplan-
tation from an asymptomatic donor to a C. difficile
chronically infected patient was reported [70], high-
lighting the risks of such therapies. However, new
approaches using targeted gut colonization or bac-
teriotherapy show promise and may provide safer
and adaptable future therapies for intestinal diseases
and infections characterized by dysbiosis [71].PROGRESS WITH ANTIVIRALS AND
VACCINES
To date, there are no specific treatments available for
norovirus disease and therapy is purely supportive,
relying on rehydration. The increased recognition of
the severity of norovirus disease and associated
mortality in the immunocompromised and infirm
has spurred interest in antivirals. Progress in this
area is severely hampered by the lack of a cell culture
system or appropriate animal models. The ability to
produce norovirus virus like particles (VLPs) to userized reproduction of this article is prohibited.
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Norovirus in healthcare settings Iturriza-Go´mara and Lopmanas a surrogate for the study of norovirus–ligand
attachment does provide an indirect andmore labor
intensive approach to develop and evaluate specific
therapies targeting viral entry. Carbohydrates and
analogs that mimic the molecular structures of
those recognized by noroviruses have been ident-
ified in recent years, shown to bind to VLPs in vitro
and also inhibit binding of VLPs to jejunal biopsies
[72]. Drugs and compounds that could potentially
inhibit viral replication or virus protein synthesis
can also be possible therapeutic agents, although at
present the lack of an in vitro or an ideal surrogate
system means progress in this area is slow [73].
Kaufman et al. [56
&&
] recently described the potential
for antiviral therapies for the immunocompro-
mised, and considered the wider population
benefits that may be gained beyond the successful
treatment of the individual patients in addition to
proposing options for the design of clinical trials for
evaluating the efficacy of potential antinorovirus
therapies in immunocompromised patients.
Significant progress has been made in develop-
ing nonreplicating VLP-based vaccines against nor-
ovirus. These have shown to be immunogenic and
to confer a significant degree of protection (48%
against disease and 26% against infection) to chal-
lenge in volunteer studies [74]. Multivalent vaccines
can induce broad mucosal and systemic blocking
antibodies [75,76]. These promising results may, in
the near future, lead to phase III clinical trials in
different target populations [74]. One of the chal-
lenges that any norovirus vaccine must overcome is
the need to elicit cross-reactive protection against
the diverse population of norovirus genotypes and
variant strains within genotypes. Norovirus GII.4
strains are the most prevalent, and their constant
evolution is associated with epidemic waves every
2–4 years because of the emergence of antigenically
novel strains that escape herd immunity [29–31].
Therefore, an efficacious norovirus vaccine must be
able to protect against a variety of antigenically
diverse variants of GII.4 noroviruses. If the strategy
of employing consensus VLPs to provide protection
against the evolving blockade epitopes is not
successful, vaccines may need to be reformulated
regularly, as is done for influenza vaccines, to
incorporate novel antigens [53,77]. However, con-
sensus or chimeric VLP approaches that require only
the mutation of certain epitopes may provide a
system that is more amenable for rapid production
of vaccines that can adapt to emerging strains.CONCLUSION
As such a wide range of the population is affected by
norovirus, defining a target group for interventions,Copyright © Lippincott Williams & Wilkins. Unau
0951-7375  2014 Wolters Kluwer Health | Lippincott Williams & Wilkand vaccination in particular, is a challenge. Target-
ing a norovirus vaccine to protect the populations at
higher risk of disease may include infants, the eld-
erly, and the immunocompromised. Themajority of
outbreaks occur among the elderly in hospitals or in
long-term residential care facilities; therefore, a
vaccine to protect this population is a priority.
Vaccination of infants will address the most com-
mon cause of pediatric hospitalization due to gastro-
enteritis in countries in which rotavirus vaccine is in
use [5
&
]. In addition, immunizing children could
have important indirect benefits by limiting the
transmission of norovirus in the general population.
Before vaccines are ready to be rolled out for wide-
spread use, there are still important questions that
need to be answered such as the immunogenicity in
infants and the elderly, which may be substantially
reduced because of differences in exposure history
and immune state and duration of protection.
As immunocompromised hospital patients may
have chronic diarrhea and norovirus excretion,
development of effective antiviral treatments and/
or passive immunotherapy is a priority. Such thera-
pies may not only benefit the affected patient
directly, but may also benefit efforts to control
transmission in the hospital, especially in transplant
and oncology care units, in which most patients are
immunosuppressed and at high risk of severe nor-
ovirus disease outcomes.
Given the high economic burden of nosocomial
norovirus outbreaks, second only in the United
Kingdom to the cost associated with urinary tract
infections [4], a full cost–benefit analysis should
inform refurbishment initiatives and future hospital
design in that country, and perhaps others with
similar hospital design structures. More generally,
we advocate for a stronger evidence base for infec-
tion prevention and control of norovirus in health-
care settings, well designed controlled trials, or,
where that is impractical or unethical, observational
studies should be conducted on interventions,
including ward closure, disinfection regimes, and
cohorting strategies.
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